Clinical Trials Directory

Trials / Completed

CompletedNCT03650023

A Crossover Trial of Chitosan Oligosaccharide on Post Prandial Glucose Control in Subjects With Normal, IFG and IGT

A Crossover Trial of Chitosan Oligosaccharide (GO2KA1) on Post Prandial Glucose Control in Subjects With Normal Blood Glucose, Impaired Fasting Glucose and Impaired Glucose Tolerance

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
37 (actual)
Sponsor
Yonsei University · Academic / Other
Sex
All
Age
20 Years – 74 Years
Healthy volunteers
Accepted

Summary

It is well known that Chitosan oligosaccharide is low molecular weight and water soluble and chitosan oligosaccharide has been shown to reduce blood cholesterol and blood pressure, increase immunity, and enhance antitumor properties. the effect of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with normal blood glucose, impaired fasting glucose and impaired glucose tolerance.

Detailed description

A randomized, double-blinded, controlled, cross-over trial was conducted to verify the effects of chitosan oligosaccharide (GO2KA1). forty healthy male and female subjects aged 20-75 years with normal blood glucose, impaired fasting glucose and impaired glucose tolerance were recruited. The subjects visited the research site twice over with a seven-day interval after an overnight fast at least 12 hr. On the screening visit, the participants were the 2-hr oral glucose tolerance test (OGTT) was conducted. And they were separated normal blood glucose, impaired fasting glucose and impaired glucose tolerance. On the first visit, the participants were randomly assigned to consume a test or placebo product \[test product: chitosan oligosaccharide powder 500mg (GO2KA1); placebo product: white egg powder 500mg\] and ingested the assigned product. On the second visit, the participants consumed the other product that they did not eat on the first visit. On both visit day, the 2-hr oral sucrose tolerance test (OSTT) was conducted and started at 8:00 in the morning; venous blood samples were collected before (0 hr) and after ingestion (0.5, 1 and 2 hr) of the products.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTChitosan Oligosaccharide (GO2KA1)Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
DIETARY_SUPPLEMENTWhite eggWhite egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.

Timeline

Start date
2018-05-09
Primary completion
2018-07-25
Completion
2018-07-25
First posted
2018-08-28
Last updated
2018-08-28

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT03650023. Inclusion in this directory is not an endorsement.